|
1.
|
Pantel K, Brakenhoff RH and Brandt B:
Detection, clinical relevance and specific biological properties of
disseminating tumour cells. Nat Rev Cancer. 8:329–340. 2008.
|
|
2.
|
Fehm T, Müller V, Alix-Panabières C and
Pantel K: Micrometastatic spread in breast cancer: detection,
molecular characterization and clinical relevance. Breast Cancer
Res. 10:12008.
|
|
3.
|
Alix-Panabieres C, Vendrell JP, Slijper M,
Pelle O, Barbotte E, Mercier G, Jacot W, Fabbro M and Pantel K:
Full length cytokeratin-19 is released by human tumor cells: a
potential role in metastatic progression of breast cancer. Breast
Cancer Res. 11:392009.
|
|
4.
|
Barak CV, Goike H, Panaretakis KW and
Einarsson R: Clinical utility of cytokeratins as tumor markers.
Clin Biochem. 37:529–540. 2004.
|
|
5.
|
Coulombe PA and Omary MB: ‘Hard’ and
‘soft’ principles defining the structure, function and regulation
of keratin intermediate filaments. Curr Opin Cell Biol. 14:110–122.
2002.
|
|
6.
|
Linder S: Cytokeratin markers come of age.
Tumor Biol. 28:189–195. 2007.
|
|
7.
|
Scott LC, Evans TR, Cassidy J, Harden S,
Paul J, Ullah R, O'Brien V and Brown R: Cytokeratin 18 in plasma of
patients with gastrointestinal adenocarcinoma as a biomarker of
tumour response. Br J Cancer. 101:410–417. 2009.
|
|
8.
|
Björklund B and Björklund V: Specificity
and basis of the tissue polypeptide antigen. Cancer Detect Prev.
6:41–50. 1983.
|
|
9.
|
Stigbrand T: The versatility of
cytokeratins as tumor markers. Tumour Biol. 22:1–3. 2001.
|
|
10.
|
Sheard MA, Vojtesek B, Simickova M and
Valik D: Release of cytokeratin-18 and -19 fragments (TPS and CYFRA
21-1) into the extracellular space. J Cell Biochem. 85:670–677.
2002.
|
|
11.
|
Oehr P, Vacata V, Ruhlmann J and Rink H:
Computer modeling of cytokeratin release in clinical oncology.
Anticancer Res. 17:3111–3112. 1997.
|
|
12.
|
Kramer G, Erdal H, Mertens HJ, Nap M,
Mauermann J, Steiner G, Marberger M, Bivén K, Shoshan MC and Linder
S: Differentiation between cell death modes using measurements of
different soluble forms of extracellular cytokeratin 18. Cancer
Res. 64:1751–1756. 2004.
|
|
13.
|
Dohmoto K, Hojo S, Fujita J, Yang Y, Ueda
Y, Bandoh S, Yamaji Y, Ohtsuki Y, Dobashi N, Ishida T and Takahara
J: The role of caspase 3 in producing cytokeratin 19 fragment
CYFRA21-1 in human lung cancer cell lines. Int J Cancer.
91:468–473. 2001.
|
|
14.
|
Ausch C, Buxhofer-Ausch V, Olszewski U,
Hinterberger W, Ogris E, Schiessel R and Hamilton G:
Caspase-cleaved cytokeratin 18 fragment (M30) as marker of
postoperative residual tumor load in colon cancer patients. Eur J
Surg Oncol. Feb 28–2009.(Epub ahead of print).
|
|
15.
|
Ausch C, Buxhofer-Ausch V, Olszewski U,
Schiessel R, Ogris E, Hinterberger W and Hamilton G: Circulating
cytokeratin 18 fragment M65 – a potential marker of malignancy in
colorectal cancer patients. J Gastrointest Surg. Sept 2–2009.(Epub
ahead of print).
|
|
16.
|
Buxhofer-Ausch V, Ausch C, Kitzweger E,
Mollik M, Reiner-Concin A, Ogris E, Stampfl M, Hamilton G,
Schiessel R and Hinterberger W: Spontaneous changes in tumour cell
dissemination to bone marrow in colorectal cancer. Colorectal Dis.
May 18–2009.(Epub ahead of print).
|
|
17.
|
Bidard FC, Vincent-Salomon A,
Sigal-Zafrani B, et al: Time to metastatic relapse and breast
cancer cell dissemination in bone marrow at metastatic relapse.
Clin Exp Metastasis. 25:871–875. 2008.
|
|
18.
|
Weitz J, Kienle P, Lacroix J, Willeke F,
Benner A, Lehnert T, Herfarth C and von Knebel Doeberitz M:
Dissemination of tumor cells in patients undergoing surgery for
colorectal cancer. Clin Cancer Res. 4:343–348. 1998.
|
|
19.
|
Retsky MW, Demicheli R, Hrushesky WJ, Baum
M and Gukas ID: Dormancy and surgery-driven escape from dormancy
help explain some clinical features of breast cancer. APMIS.
116:730–741. 2008.
|
|
20.
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell
LL, Polyak K, Brisken C, Yang J and Weinberg RA: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008.
|
|
21.
|
Abraham MC and Shaham S: Death without
caspases, caspases without death. Trends Cell Biol. 14:184–193.
2004.
|
|
22.
|
Launay S, Hermine O, Fontenay M, Kroemer
G, Solary E and Garrido C: Vital functions for lethal caspases.
Oncogene. 24:5137–5148. 2005.
|
|
23.
|
Willipinski-Stapelfeldt B, Riethdorf S,
Assmann V, et al: Changes in cytoskeletal protein composition
indicative of an epithelial-mesenchymal transition in human
micrometastatic and primary breast carcinoma cells. Clin Cancer
Res. 11:8006–8014. 2005.
|
